Gene info: ID 152

Gene: ADRA2C

GENE ID: 152

Synonyms: ADRA2L2|ADRA2RL2|ADRARL2|ALPHA2CAR

Description: adrenoceptor alpha 2C

Gene type: protein-coding

Location: 4p16.3

dbXrefs: Ensembl:ENSG00000184160 MIM:104250 Vega:OTTHUMG00000159830 UniprotKB:P18825

RefSeq: NG_012640.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: CD|ND|AD

# Publications: 2

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 5.420e-1 (AD) 3.497e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
PWWP2B	0.787
YJEFN3	0.771
NR2F6	0.761
SSBP4	0.744
CNIH2	0.737
KLF16	0.735
ZNF771	0.734
KCNG1	0.733
DUSP8	0.732
FAM155B	0.723

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
CDNF	-0.496
ENPEP	-0.478
MATN3	-0.47
ADAMTS4	-0.444
CTBS	-0.441
CCDC15	-0.427
CCT6B	-0.416
CD109	-0.415
BARD1	-0.414
SEPT10	-0.411

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00246	Ziprasidone	Small Molecule	146939-27-7	Approved	Target
DB00248	Cabergoline	Small Molecule	81409-90-7	Approved	Target
DB00268	Ropinirole	Small Molecule	91374-21-9	Approved\|Investigational	Target
DB00334	Olanzapine	Small Molecule	132539-06-1	Approved\|Investigational	Target
DB00363	Clozapine	Small Molecule	5786-21-0	Approved	Target
DB00368	Norepinephrine	Small Molecule	51-41-2	Approved	Target
DB00370	Mirtazapine	Small Molecule	85650-52-8	Approved	Target
DB00408	Loxapine	Small Molecule	1977-10-2	Approved	Target
DB00413	Pramipexole	Small Molecule	104632-26-0	Approved\|Investigational	Target
DB00484	Brimonidine	Small Molecule	59803-98-4	Approved	Target
DB00575	Clonidine	Small Molecule	4205-90-7	Approved	Target
DB00589	Lisuride	Small Molecule	18016-80-3	Approved\|Investigational	Target
DB00668	Epinephrine	Small Molecule	51-43-4	Approved	Target
DB00697	Tizanidine	Small Molecule	51322-75-9	Approved\|Investigational	Target
DB00714	Apomorphine	Small Molecule	58-00-4	Approved\|Investigational	Target
DB00734	Risperidone	Small Molecule	106266-06-2	Approved\|Investigational	Target
DB00797	Tolazoline	Small Molecule	59-98-3	Approved	Target
DB00800	Fenoldopam	Small Molecule	67227-56-9	Approved	Target
DB00925	Phenoxybenzamine	Small Molecule	59-96-1	Approved	Target
DB00935	Oxymetazoline	Small Molecule	1491-59-4	Approved\|Investigational	Target
DB01136	Carvedilol	Small Molecule	72956-09-3	Approved\|Investigational	Target
DB01142	Doxepin	Small Molecule	1668-19-5	Approved\|Investigational	Target
DB01186	Pergolide	Small Molecule	66104-22-1	Approved\|Investigational\|Withdrawn	Target
DB01200	Bromocriptine	Small Molecule	25614-03-3	Approved\|Investigational	Target
DB01224	Quetiapine	Small Molecule	111974-69-7	Approved	Target
DB01238	Aripiprazole	Small Molecule	129722-12-9	Approved\|Investigational	Target
DB01267	Paliperidone	Small Molecule	144598-75-4	Approved	Target
DB01363	Ephedra	Small Molecule	-	Approved\|Nutraceutical\|Withdrawn	Target
DB01392	Yohimbine	Small Molecule	146-48-5	Approved\|Investigational	Target
DB01403	Methotrimeprazine	Small Molecule	60-99-1	Approved\|Investigational	Target
DB01577	Methamphetamine	Small Molecule	537-46-2	Approved\|Illicit	Target
DB04855	Dronedarone	Small Molecule	141626-36-0	Approved	Target
DB04946	Iloperidone	Small Molecule	133454-47-4	Approved	Target
DB05461	OPC-28326	Small Molecule	-	Investigational	Target
DB05492	Epicept NP-1	Small Molecule	-	Investigational	Target
DB06148	Mianserin	Small Molecule	24219-97-4	Approved\|Investigational	Target
DB06216	Asenapine	Small Molecule	65576-45-6	Approved	Target
DB06229	Ocaperidone	Small Molecule	129029-23-8	Investigational	Target
DB06262	Droxidopa	Small Molecule	23651-95-8	Approved\|Investigational	Target
DB06694	Xylometazoline	Small Molecule	526-36-3	Approved\|Investigational	Target
DB08815	Lurasidone	Small Molecule	367514-87-2	Approved\|Investigational	Target
DB08838	Agmatine	Small Molecule	306-60-5	Experimental\|Investigational	Target
DB09128	Brexpiprazole	Small Molecule	913611-97-9	Approved\|Investigational	Target
DB11124	Racepinephrine	Small Molecule	329-65-7	Approved	Target
DB00217	Bethanidine	Small Molecule	55-73-2	Approved	Target
DB00397	Phenylpropanolamine	Small Molecule	14838-15-4	Approved\|Withdrawn	Target
DB00477	Chlorpromazine	Small Molecule	50-53-3	Approved\|Investigational	Target
DB00540	Nortriptyline	Small Molecule	72-69-5	Approved	Target
DB00543	Amoxapine	Small Molecule	14028-44-5	Approved	Target
DB00841	Dobutamine	Small Molecule	34368-04-2	Approved	Target
DB00934	Maprotiline	Small Molecule	10262-69-8	Approved\|Investigational	Target
DB01049	Ergoloid mesylate	Small Molecule	8067-24-1	Approved	Target
DB01151	Desipramine	Small Molecule	50-47-5	Approved\|Investigational	Target
DB06678	Esmirtazapine	Small Molecule	61337-87-9	Investigational	Target
DB06707	Levonordefrin	Small Molecule	829-74-3	Approved	Target
DB09167	Dosulepin	Small Molecule	113-53-1	Approved	Target
DB09194	Etoperidone	Small Molecule	52942-31-1	Withdrawn	Target
DB09195	Lorpiprazole	Small Molecule	108785-69-9	Approved	Target
DB09202	Cirazoline	Small Molecule	59939-16-1	Experimental	Target
DB09304	Setiptiline	Small Molecule	57262-94-9	Approved	Target
DB13025	Tiapride	Small Molecule	51012-32-9	Approved\|Investigational	Target
DB00182	Amphetamine	Small Molecule	300-62-9	Approved\|Illicit\|Investigational	Target
DB01365	Mephentermine	Small Molecule	100-92-5	Approved	Target
DB09205	Moxisylyte	Small Molecule	54-32-0	Approved\|Investigational	Target
DB09229	Aranidipine	Small Molecule	86780-90-7	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C049325	1,2-dithiol-3-thione	"1,2-dithiol-3-thione results in increased expression of ADRA2C mRNA"	19162173
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of ADRA2C mRNA"	19114083
C058525	2-methoxyidazoxan	ADRA2C protein binds to 2-methoxyidazoxan	20030735
C058525	2-methoxyidazoxan	Epinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]	20030735
C058525	2-methoxyidazoxan	Norepinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]	20030735
C058525	2-methoxyidazoxan	Oxymetazoline inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]	20030735
C058525	2-methoxyidazoxan	xylometazoline inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]	20030735
C058525	2-methoxyidazoxan	ADRA2C affects the susceptibility to 2-methoxyidazoxan	10336518
C058525	2-methoxyidazoxan	2-methoxyidazoxan binds to and results in decreased activity of ADRA2C protein	10336518
D020875	Enkephalin, Ala(2)-MePhe(4)-Gly(5)-	"ADRA2C results in increased susceptibility to Enkephalin, Ala(2)-MePhe(4)-Gly(5)-"	8987795
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of ADRA2C mRNA	16483693
D000661	Amphetamine	ADRA2C protein results in decreased susceptibility to Amphetamine	11358337
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of ADRA2C mRNA	21632981\|2231617
D004958	Estradiol	Estradiol results in increased expression of ADRA2C mRNA	23019147
D004958	Estradiol	Estradiol results in decreased expression of ADRA2C mRNA	15289156
C543008	bis(4-hydroxyphenyl)sulfone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ADRA2C mRNA	28628672
C006780	bisphenol A	bisphenol A results in decreased expression of ADRA2C mRNA	25181051
D002118	Calcium	[Epinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium	20030735
D002118	Calcium	[Norepinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium	20030735
D002713	Chlorine	[Ozone co-treated with Chlorine] results in increased expression of ADRA2C mRNA	18636392
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of ADRA2C mRNA	17452286
D002994	Clofibrate	Clofibrate results in decreased expression of ADRA2C mRNA	17585979
D003000	Clonidine	ADRA2C protein results in increased susceptibility to Clonidine	16814767
D003000	Clonidine	Clonidine binds to and results in increased activity of ADRA2C protein	10217548
D003000	Clonidine	ADRA2C results in increased susceptibility to Clonidine	8987795
D005576	Colforsin	AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]	24701590
D005576	Colforsin	AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA]	24701590
D005576	Colforsin	Colforsin affects the localization of ADRA2C protein	24701590
D005576	Colforsin	Colforsin results in increased expression of ADRA2C mRNA	24701590
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of ADRA2C mRNA	19549813
D003671	DEET	[fipronil co-treated with DEET] results in increased expression of ADRA2C mRNA	27091632
D003907	Dexamethasone	Dexamethasone results in increased expression of ADRA2C mRNA	25047013
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ADRA2C mRNA	28628672
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of ADRA2C mRNA	15620428
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased expression of ADRA2C mRNA	15289156
D004298	Dopamine	Dopamine binds to ADRA2C protein	10336518
D004837	Epinephrine	ADRA2C promotes the reaction [Epinephrine results in increased expression of CCND1 protein]	17680988
D004837	Epinephrine	ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]	17680988
D004837	Epinephrine	ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]	17680988
D004837	Epinephrine	ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]	17680988
D004837	Epinephrine	Epinephrine binds to and results in increased activity of ADRA2C protein	20030735
D004837	Epinephrine	[Epinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium	20030735
D004837	Epinephrine	Epinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]	20030735
C082360	fipronil	[fipronil co-treated with DEET] results in increased expression of ADRA2C mRNA	27091632
C082360	fipronil	fipronil results in increased expression of ADRA2C mRNA	27091632
D005419	Flavonoids	Flavonoids results in decreased expression of ADRA2C mRNA	18035473
C069837	fullerene C60	fullerene C60 results in decreased expression of ADRA2C mRNA	19167457
D019833	Genistein	Genistein results in increased expression of ADRA2C mRNA	23019147
D019833	Genistein	Genistein results in decreased expression of ADRA2C mRNA	15289156
D019833	Genistein	[Genistein co-treated with Methoxychlor] results in decreased expression of ADRA2C mRNA	21782745
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ADRA2C mRNA	28628672
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ADRA2C mRNA	28628672
C518829	JP-1302	JP-1302 binds to and results in decreased activity of ADRA2C protein	19429072
C410337	K 7174	K 7174 results in decreased expression of ADRA2C mRNA	24086573
C054290	L 657743	[L 657743 binds to and results in decreased activity of ADRA2C protein] which results in decreased susceptibility to oxcarbazepine	17959985
D000069056	Lurasidone Hydrochloride	Lurasidone Hydrochloride binds to ADRA2C protein	20404009
D008731	Methoxychlor	[Genistein co-treated with Methoxychlor] results in decreased expression of ADRA2C mRNA	21782745
C445068	methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate	"methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate results in decreased activity of ADRA2C protein"	28790194
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of ADRA2C mRNA"	20188158
D008790	Metoprolol	[ADRB1 gene polymorphism co-treated with ADRA2C gene polymorphism] affects the susceptibility to Metoprolol	17496726
C048599	N(6)-cyclopentyladenosine	ADRA2C results in increased susceptibility to N(6)-cyclopentyladenosine	8987795
C031721	naphthalene	naphthalene analog results in decreased expression of ADRA2C mRNA	24976557
D009532	Nickel	Nickel results in increased expression of ADRA2C mRNA	18812211
C025256	nonylphenol	nonylphenol results in decreased expression of ADRA2C mRNA	15620428
D009638	Norepinephrine	Norepinephrine binds to and results in increased activity of ADRA2C protein	20030735
D009638	Norepinephrine	[Norepinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium	20030735
D009638	Norepinephrine	Norepinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]	20030735
D009638	Norepinephrine	[ADRA2A protein mutant form co-treated with ADRA2C protein mutant form] results in increased abundance of Norepinephrine	20083574
D009638	Norepinephrine	Norepinephrine binds to ADRA2C protein	10336518
C036006	oxcarbazepine	[L 657743 binds to and results in decreased activity of ADRA2C protein] which results in decreased susceptibility to oxcarbazepine	17959985
D010109	Oxymetazoline	Oxymetazoline binds to ADRA2C protein	20030735
D010109	Oxymetazoline	Oxymetazoline inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]	20030735
D010126	Ozone	[Ozone co-treated with Chlorine] results in increased expression of ADRA2C mRNA	18636392
C029261	phenethylamine	phenethylamine binds to ADRA2C protein	20217639
D010665	Phenylpropanolamine	Phenylpropanolamine binds to ADRA2C protein	20217639
D011224	Prazosin	Prazosin binds to and results in decreased activity of ADRA2C protein	15265636
D011374	Progesterone	Progesterone results in increased expression of ADRA2C mRNA	20864642
C012526	quercitrin	quercitrin results in increased expression of ADRA2C mRNA	25193878
D012643	Selenium	Selenium results in increased expression of ADRA2C mRNA	19244175
C025462	sulindac sulfide	sulindac sulfide results in decreased expression of ADRA2C mRNA	12734198
D013578	Synephrine	Synephrine binds to ADRA2C protein	20217639
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of ADRA2C mRNA	26377647
D014212	Tretinoin	Tretinoin results in decreased expression of ADRA2C mRNA	23830798
D014212	Tretinoin	Tretinoin results in increased expression of ADRA2C mRNA	23724009
C057693	troglitazone	troglitazone results in increased expression of ADRA2C mRNA	21515302
D014520	Urethane	Urethane results in decreased expression of ADRA2C mRNA	28818685
D014635	Valproic Acid	Valproic Acid results in increased methylation of ADRA2C gene	29154799
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of ADRA2C gene	25560391
D014810	Vitamin E	Vitamin E results in increased expression of ADRA2C mRNA	19244175
C111237	vorinostat	vorinostat results in decreased expression of ADRA2C mRNA	27188386
C009695	xylometazoline	xylometazoline binds to ADRA2C protein	20030735
C009695	xylometazoline	xylometazoline inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]	20030735

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004935	adrenergic receptor activity	-	IBA	21873635
GO:0004938	alpha2-adrenergic receptor activity	-	IDA	17215105
GO:0005515	protein binding	-	IPI	16531006
GO:0031694	alpha-2A adrenergic receptor binding	-	IPI	16605244
GO:0042803	protein homodimerization activity	-	IDA	16605244
GO:0046982	protein heterodimerization activity	-	IPI	16605244
GO:0051379	epinephrine binding	-	IDA	17215105

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0007186	G-protein coupled receptor signaling pathway	-	TAS	-
GO:0007188	adenylate cyclase-modulating G-protein coupled receptor signaling pathway	-	IBA	21873635
GO:0007267	cell-cell signaling	-	IBA	21873635
GO:0007267	cell-cell signaling	-	TAS	9371698
GO:0007565	female pregnancy	-	IEA	-
GO:0010700	negative regulation of norepinephrine secretion	-	NAS	16531006
GO:0010700	negative regulation of norepinephrine secretion	-	TAS	19477270
GO:0030168	platelet activation	-	IEA	-
GO:0032148	activation of protein kinase B activity	-	IDA	17215105
GO:0032811	negative regulation of epinephrine secretion	-	NAS	16531006
GO:0035625	epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway	-	IDA	17215105
GO:0043410	positive regulation of MAPK cascade	-	IDA	17215105
GO:0045666	positive regulation of neuron differentiation	-	IDA	17215105
GO:0045907	positive regulation of vasoconstriction	-	IEA	-
GO:0050796	regulation of insulin secretion	-	TAS	-
GO:0051930	regulation of sensory perception of pain	-	IEA	-
GO:0070473	negative regulation of uterine smooth muscle contraction	-	IEA	-
GO:0071875	adrenergic receptor signaling pathway	-	IDA	17215105
GO:0071880	adenylate cyclase-activating adrenergic receptor signaling pathway	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005737	cytoplasm	-	IDA	16605244
GO:0005768	endosome	-	TAS	10196213
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IBA	21873635
GO:0005887	integral component of plasma membrane	-	IDA	16605244
GO:0043679	axon terminus	-	IEA	-

KEGG ID	KEGG Term
hsa04080	Neuroactive ligand-receptor interaction

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-1430728	Metabolism	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-163685	Integration of energy metabolism	TAS
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)	TAS
R-HSA-375280	Amine ligand-binding receptors	TAS
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-390696	Adrenoceptors	TAS
R-HSA-392023	Adrenaline signalling through Alpha-2 adrenergic receptor	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-400042	Adrenaline,noradrenaline inhibits insulin secretion	TAS
R-HSA-418594	G alpha (i) signalling events	TAS
R-HSA-418597	G alpha (z) signalling events	TAS
R-HSA-422356	Regulation of insulin secretion	TAS
R-HSA-500792	GPCR ligand binding	TAS
R-HSA-5683826	Surfactant metabolism	TAS
R-HSA-76002	Platelet activation, signaling and aggregation	TAS
R-HSA-76009	Platelet Aggregation (Plug Formation)	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
16636200	Do allelic variants in alpha2A and alpha2C adrenergic receptors predispose to hypertension in blacks? (2006 Jun)	Li JL	Hypertension
11317218	An in-frame deletion in the alpha(2C) adrenergic receptor is common in African--Americans. (2001 Mar)	Feng J	Mol Psychiatry